Gelonghui May 20 丨 Lanfan Medical (002382flyingtigerdragon.SZ) announcedflyingtigerdragon, combined with Lanfan Baisheng's own development needs and capital operation planningflyingtigerdragonBased on the comprehensive consideration of the company and in accordance with the follow-up financing arrangements agreed in the "A1 Round Investment Agreement", Lanfan Baisheng plans to continue to introduce the A2 round strategic investor Daxing Airport Development Fund to increase capital and share shares. This time, the investor plans to increase capital to Lanfan Baisheng in cash with a total amount of RMB 100 million, and subscribe for 254 new registered capital of Lanfan Baishengflyingtigerdragon.82.79 million yuan, corresponding to 2.0000% of the entire equity of Lanfan Baisheng after this transaction.
The company, the company's wholly-owned subsidiary NVTHK and the A1 investors waived the pre-emptive rights for this capital increase. After the completion of this capital increase, Lanfan Baisheng's registered capital will increase from RMB 124.865671 million to RMB 127.41395 million, and the company's equity ratio in Lanfan Baisheng will change from 81.6327% to 80.0000%. Lanfan Baisheng will still be a controlling subsidiary of the company and will continue to be included in the scope of the company's consolidated statements.
